Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Visit

EHA 2024 | The safety and efficacy of the Syk inhibitor sovleplenib in heavily pre-treated Hodgkin lymphoma

Paolo Strati • 3 Jun 2024

EHA 2024

Hodgkin Lymphoma Lymphoma Sovleplenib

Paolo Strati, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, comments on a study investigating the safety and efficacy of sovleplenib, a spleen tyrosine kinase (Syk) inhibitor, in patients with heavily pre-treated Hodgkin lymphoma (HL) (NCT03779113). The safety profile was manageable, and the agent successfully induced durable complete remission (CR) and measurable residual disease (MRD) eradication in a proportion of patients. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

BTK inhibitors in the treatment of DLBCL: trials investigating these agents

Paolo Strati • 10 Dec 2023

Updates on the Smart Stop trial: the potential for a chemo-free regimen in the frontline for DLBCL

Paolo Strati • 10 Dec 2023

Loncastuximab tesirine as a consolidation strategy post-CAR T-cell therapy in DLBCL

Paolo Strati • 10 Dec 2023

Autologous SIRPα- low macrophages (SIRPant-M) enhance immune anti-tumor activity in R/R NHL

Paolo Strati • 10 Dec 2023

Related Videos

Selecting between BTK inhibitors in MCL & addressing resistance to these agents

Alexey Danilov • 14 Jun 2024

Preliminary results from a Phase Ib trial of AS-1763, a novel non-covalent BTKi, in CLL/MCL

Nitin Jain • 15 Jun 2024

Findings from the Ro-CHOP trial in patients with R/R PTCL

Vincent Camus • 14 Jun 2024

Insights into ongoing research on BTK degraders for lymphoid malignancies

Alexey Danilov • 14 Jun 2024